S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

BIAF bioAffinity Technologies Inc

0.8898

-0.0602 (-6.34%)

28 Dec 2024 - Closed

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more bioAffinity Technologies Charts.

bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more bioAffinity Technologies Charts.

bioAffinity Technologies Inc News

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19
Wednesday 18 December 2024 (2 weeks ago) • Business Wire

bioAffinity Technologies Set for Continued Expansion in 2025
Friday 13 December 2024 (2 weeks ago) • Business Wire

Veterans’ Research Foundation Spotlights CyPath® Lung’s Addition to the Federal Supply Schedule
Friday 6 December 2024 (3 weeks ago) • Business Wire

bioAffinity Technologies Reports $2.4 Million Revenue for Q3 2024
Friday 15 November 2024 (1 month ago) • Business Wire

bioAffinity Technologies Appoints New Chief Science Officer to Spearhead Product Development
Tuesday 5 November 2024 (2 months ago) • Business Wire

bioAffinity Technologies Announces Award of Japanese Patent for CyPath® Lung
Wednesday 30 October 2024 (2 months ago) • Business Wire

WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement
Tuesday 22 October 2024 (2 months ago) • PR Newswire (US)

bioAffinity Technologies Announces Closing of $2.6 Million Registered Direct Offering & Concurrent Private Placement
Tuesday 22 October 2024 (2 months ago) • Business Wire

WallachBeth Capital Announces Pricing of bioAffinity Technologies $2.66 Million Registered Direct Offering & Concurrent Private Placement
Saturday 19 October 2024 (2 months ago) • PR Newswire (US)

bioAffinity Technologies Announces Pricing of $2.66 Million Registered Direct Offering & Concurrent Private Placement
Saturday 19 October 2024 (2 months ago) • Business Wire

bioAffinity’s CyPath® Lung Cancer Test Supported by Newly Published Flow Cytometry Guidelines
Wednesday 16 October 2024 (2 months ago) • Business Wire

bioAffinity Technologies Names J. Michael Edwards as Chief Financial Officer
Thursday 10 October 2024 (3 months ago) • Business Wire

More bioAffinity Technologies Inc News Articles

Vontobel Financial Produ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions